Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy - PubMed
4 hours ago
- #Hepatitis B
- #Innate Immunity
- #Biomarker
- Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients on nucleoside analogue therapy, offering potential as a biomarker and therapeutic target.
- Single-cell RNA sequencing identified higher IL-1β expression in CD14+CD16- classical monocytes from patients with declining HBsAg, along with enhanced antigen presentation and phagocytosis.
- In vitro, recombinant IL-1β suppressed HBsAg secretion from HBV-producing cells in a dose-dependent manner, suggesting a direct role in reducing antigen levels.
- Elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71 in a longitudinal cohort and was confirmed as an independent predictor in multivariate analysis.